Drugmakers argue the 340B program has expanded far beyond helping health providers that serve low-income patients.


<div class="paywall-container">
<div class="textbox">
<h4 style="padding: 0 0 20px"> <a href="https://checkout.bostonherald.com/?&amp;g2i_or_o=Internet&amp;g2i_or_p=mg2pw20&amp;g2i_source=MD&amp;g2i_medium=sspw&amp;g2i_campaign=MG2PW20-sspw&amp;returnUrl=https3A2F2Fwww.bostonherald.com2F">Subscribe</a> to continue reading this article.</h4>
<h4> Already subscribed? <a href="/2024/09/05/states-force-drugmakers-to-keep-selling-cheaper-meds-under-federal-program//login?&amp;returnUrl=https%3A%2F%2Fwww.bostonherald.com%2F2024%2F09%2F05%2Fstates-force-drugmakers-to-keep-selling-cheaper-meds-under-federal-program%2F">To login in, click here.</a></h4>
</div>
</div>


Originally Published: <time datetime="2024-09-05 16:04:18">September 5, 2024 at 4:04 p.m.</time>

Drugmakers argue the 340B program has expanded far beyond helping health providers that serve low-income patients.{ai:summary}<p>Drugmakers contend that the 340B program has grown beyond its intended purpose of assisting health providers serving low-income patients. They assert that this expansion has led to misuse of funds and resources.  </p><p>#politics</p>

States force drugmakers to keep selling cheaper meds under federal program

Subscribe to continue reading this article.

Already subscribed? To login in, click here.

Loading...